Evidence map›Paper›PMID 34414673›Full record

ArticleCancer medicine2021

Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.

Hisao Imai, Takayuki Kishikawa, Hiroyuki Minemura, Yutaka Yamada, Tatsuya Ibe, Ou Yamaguchi, Atsuto Mouri, Yoichiro Hamamoto, Kenya Kanazawa, Takashi Kasai and 5 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 5 pooled it
2.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 5 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Hisao ImaiDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan.ORCID 0000-0003-3097-4255
Takayuki KishikawaDivision of Thoracic Oncology, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan.ORCID 0000-0002-8957-4814
Hiroyuki MinemuraDepartment of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.ORCID 0000-0001-8710-1960
Yutaka YamadaDivision of Respiratory Medicine, Ibaraki Prefectural Central Hospital, Kasama, Ibaraki, Japan.ORCID 0000-0001-6823-4231
Tatsuya IbeDepartment of Pulmonary Medicine, National Hospital Organization, Nishisaitama-Chuo National Hospital, Tokorozawa, Saitama, Japan.
Ou YamaguchiDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan.ORCID 0000-0001-7194-6459
Atsuto MouriDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan.
Yoichiro HamamotoDepartment of Pulmonary Medicine, National Hospital Organization, Nishisaitama-Chuo National Hospital, Tokorozawa, Saitama, Japan.
Kenya KanazawaDepartment of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
Takashi KasaiDivision of Thoracic Oncology, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan.ORCID 0000-0002-3112-4001
Kyoichi KairaDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan.ORCID 0000-0001-5548-7686
Takayuki KaburagiDivision of Respiratory Medicine, Ibaraki Prefectural Central Hospital, Kasama, Ibaraki, Japan.
Koichi MinatoDivision of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota, Gunma, Japan.
Kunihiko KobayashiDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan.
Hiroshi KagamuDepartment of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan.
Saitama Medical University · JPFukushima Medical University · JPHyogo Prefectural Cancer Center · JPIbaraki Prefectural Central Hospital · JPNational Hospital Organization · JPTochigi Cancer Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere are no established biomarkers for predicting the efficacy of first-line pembrolizumab monotherapy in patients with high programmed death-ligand 1 (PD-L1) expression. In this study, we investigated whether the Glasgow prognostic score (GPS), neutrophil-to-lymphocyte ratio (NLR), and body mass index (BMI) can be used to evaluate the effect of first-line pembrolizumab monotherapy in patients with advanced non-small cell lung cancer (NSCLC) who express high levels of PD-L1.

methodsWe reviewed data from 142 patients with high PD-L1 expression who underwent first-line pembrolizumab monotherapy for NSCLC at six Japanese institutions between February 2017 and June 2019 and assessed the prognostic value of the GPS, NLR, and BMI. The Kaplan-Meier method and Cox proportional hazard models were used to examine differences in progression-free survival (PFS) and overall survival (OS). The GPS, NLR, and BMI were calculated using C-reactive protein and albumin concentrations, neutrophil and lymphocyte counts, and body weight and height, respectively.

resultsThe GPS independently predicted the first-line pembrolizumab monotherapy efficacy, as a good GPS (GPS 0-1) was associated with a significantly better PFS and OS compared to a poor GPS (GPS 2) (PFS: 11.8 vs. 2.9 months, p < 0.0001; OS: not reached vs. 8.3 months, p < 0.0001). Furthermore, BMI independently predicted efficacy, as patients with high BMI (BMI ≥21.4) exhibited significantly better OS compared to those with low BMI (BMI <21.4) (OS: not reached vs. 14.1 months, p = 0.006).

conclusionsAmong patients with high PD-L1 expression undergoing first-line pembrolizumab monotherapy for NSCLC, the GPS is significantly correlated with both PFS and OS, and BMI with OS, indicating that they could be used to predict treatment outcome in these patients. To the best of our knowledge, this is the first study to assess the relationship among the GPS, NLR, and BMI and survival among patients with high PD-L1 expression undergoing first-line pembrolizumab monotherapy for NSCLC.

Indexed as

AgedAged, 80 and overAntibodies, Monoclonal, HumanizedB7-H1 AntigenBody Mass IndexCarcinoma, Non-Small-Cell LungC-Reactive ProteinFemaleHumansImmune Checkpoint InhibitorsJapanKaplan-Meier EstimateLung NeoplasmsLymphocytesMaleMiddle AgedAntibodies, Monoclonal, HumanizedB7-H1 AntigenCD274 protein, humanC-Reactive ProteinImmune Checkpoint InhibitorspembrolizumabSerum Albuminbody mass indexGlasgow prognostic scorenon-small cell lung cancerpembrolizumab

Identifiers

PMID34414673
PMCPMC8525165
OpenAlexW3194517616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.